Patent application title: NOVEL AGENTS FOR THE PREVENTION OF LEISHMANIASIS
Inventors:
Jean-Loup Lemesre (Montpellier, FR)
Mireille Cavaleyra (Montpellier, FR)
Denis Sereno (Poussan, FR)
Philippe Holzmuller (Poussan, FR)
IPC8 Class: AA61K39008FI
USPC Class:
4241911
Class name: Antigen, epitope, or other immunospecific immunoeffector (e.g., immunospecific vaccine, immunospecific stimulator of cell-mediated immunity, immunospecific tolerogen, immunospecific immunosuppressor, etc.) amino acid sequence disclosed in whole or in part; or conjugate, complex, or fusion protein or fusion polypeptide including the same disclosed amino acid sequence derived from parasitic organism (e.g., dirofilaria, eimeria, trichinella, etc.)
Publication date: 2014-07-10
Patent application number: 20140193452
Abstract:
The invention relates to nucleic acid constructions, characterized in
that they comprise nucleic acids which are isolated in the sense position
and which are capable of coding for an immunogenic protein of
promastigotes or amastigotes of Leishmania, said nucleic acids responding
to one of the sequences SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID
NO:4, SEQ ID NO:5 et SEQ ID NO:11 and coding for a protein respectively
exhibiting a sequence SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9,
SEQ ID NO:10 et SEQ ID NO:12. The invention can be used for
over-expression of the genes of Leishmania coding for an
excretion/secretion antigen.Claims:
1. An isolated immunogenic glycoprotein comprising SEQ ID NO:7, said
glycoprotein being a Leishmaniasis surface antigen and an
excreted/secreted antigen with an apparent molecular weight of 42.5 kDa.
2. An isolated immunogenic glycoprotein, the protein being encoded by a nucleic acid sequence comprising SEQ ID NO:2, said glycoprotein being a Leishmaniasis surface antigen and an excreted/secreted antigen with an apparent molecular weight of 42.5 kDa.
3. A method of immunization, said method comprising administration of the glycoprotein of claim 1 to an animal such that a specific immune response is elicited.
4. A method of immunization, said method comprising administration of the glycoprotein of claim 2 to an animal such that a specific immune response is elicited.
5. An isolated peptide encoded by a nucleic acid sequence comprising SEQ ID NO:2 or comprising SEQ ID NO:7.
6. An isolated recombinant form of the immunogenic glycoprotein of claim 1.
7. An isolated recombinant form of the immunogenic glycoprotein of claim 2.
8. An isolated recombinant form of the peptide of claim 5.
Description:
[0001] This application is a divisional of U.S. application Ser. No.
10/579,749 (issued as U.S. Pat. No. 8,574,598 on Nov. 5, 2013), filed
Feb. 16, 2007 (published as US-2008-0026467 A1), which is a U.S. national
phase of international application PCT/FR2004/002955 filed 19 Nov. 2004,
which designated the U.S. and claims priority to FR 03/13555 filed 19
Nov. 2003, and FR 04/07010 filed 25 Jun. 2004, the entire contents of
each of which is incorporated herein by reference.
[0002] The invention relates to novel agents for the prevention of leishmaniasis in animals and in humans.
[0003] It relates in particular to nucleic acid molecules encoding virulence or pathogenicity factors in Leishmania and to the use thereof for producing such factors in order to develop vaccine compositions against leishmaniasis.
[0004] Leishmaniasis represents one of the six major parasitic diseases and is considered, in this respect, to be a priority by the World Health Organization (WHO). Leishmania exists in the extracellular promastigote form, inside the digestive tube of the vector insect (the sandfly), and in the intracellular amastigote form, in the mammalian host. Several molecules, including lypophosphoglycans (LPGs) or a metallo-protease called gp63, appear to play an important role in the infectious capacity and the pathogenicity of the parasite. More recently, a family of glycoproteins, called promastigote surface antigens (PSAs), has raised new interest. These PSAs are characterized by the presence of leucine-rich repeats that can be involved in protein/protein interactions and confer Th 1-type cell-mediated protective immunity in mice. In organisms, such as bacteria or plants, it appears that PSAs were involved in functions such as cell adhesion, resistance to pathogens and signal transduction.
[0005] However, no biological role has been described or suggested in Leishmania.
[0006] It has been possible for this role to be studied by the inventors by means of the technique in their possession for culturing Leishmania promastigotes and amastigotes under serum-free and axenic conditions, with a completely defined medium, i.e. in which the constituents are all defined, and which is the subject of patent FR 93 05 779 of May 13, 1993, in the name of IRD (ex ORSTOM). The mastering of this method allows them to have parasitic forms free of the contaminants introduced up until now by the culture media, and antigenic determinants in a highly purified form.
[0007] In said applicant's FR patent, the isolation and the identification of an excreted/secreted PSA (excretion/secretion antigen, abbreviated to ESA) of 38 kDa and of 45 kDa in the culture supernatant of L. amazonensis have already been described.
[0008] The inventors have presently isolated and cloned the cDNA encoding this protein and evaluated its role in the biology of the parasite by developing an additional transgenesis strategy. These studies have made it possible to demonstrate the involvement of this PSA as a virulence and/or pathogenicity factor and to develop constructs for overexpressing the Leishmania gene encoding this PSA, which makes it possible to develop agents for producing vaccine compositions against leishmaniasis.
[0009] The aim of the invention is therefore to provide nucleic acid sequences being capable of encoding PSAs of promastigote forms and of amastigote forms of Leishmania, constituting virulence and/or pathogenicity factors.
[0010] It is directed more particularly toward providing vectors for the overexpression of these PSAs, and also genetically modified parasites.
[0011] The invention is also directed toward the culture medium supernatants of the PSAs obtained, and also the isolated, purified PSAs, and the beneficial use of their properties for developing vaccine compositions against leishmaniasis.
[0012] The nucleic acid sequences of the invention correspond to isolated nucleic acids capable of encoding a PSA of promastigote forms or of amastigote forms of Leishmania, said nucleic acids corresponding to one of the sequences SEQ ID No 1, SEQ ID No 2, SEQ ID No 3, SEQ ID No 4, SEQ ID No 5 and SEQ ID No 11, and encoding PSAs having the sequences, respectively, SEQ ID No 6, SEQ ID No 7, SEQ ID No 8, SEQ ID No 9, SEQ ID No 10 and SEQ ID No 12.
[0013] The nucleic acid sequences of the invention are more especially sequences of cDNA clones belonging to a family corresponding to the characteristics illustrated by FIG. 2 and comprising in particular a SalI restriction site and two HindIII restriction sites, with a stop codon located downstream of the first HindIII site.
[0014] The invention is directed in particular toward the cDNA clones of said family comprising an EcoRV and/or PstI restriction site between the two sites SalI and HindIII, or on either side of the SalI site.
[0015] The invention is also directed toward the isolated immunogenic proteins, characterized in that they have a sequence as encoded by the nucleic acids defined above. It is directed in particular toward the proteins corresponding to the sequences SEQ ID No 6, SEQ ID No 7, SEQ ID No 8, SEQ ID No 9, SEQ ID No 10 or SEQ ID No 12.
[0016] These proteins belong to the "promastigote surface antigen" (abbreviated to PSA) family and possess characteristic regions illustrated in FIGS. 3A and 3B. These proteins can be post-translationally modified by means of N-glycosylations, phosphorylations and anchoring of a GPI. They possess a hydrophobic signal peptide in the carboxy-terminal position.
[0017] The inventors have obtained constructs that make it possible to express the sequences defined above, in the sense position, in an expression vector, by directional cloning of said sequences.
[0018] The invention is therefore directed toward nucleic acid constructs, characterized in that they comprise isolated nucleic acids in the sense position, capable of encoding an immunogenic protein of promastigote forms or of amastigote forms of Leishmania, these proteins corresponding to one of the sequences SEQ ID No 6, SEQ ID No 7, SEQ ID No 8, SEQ ID No 9, SEQ ID No 10 and SEQ ID No 12.
[0019] The invention is directed in particular toward the nucleic acid constructs comprising sequences of cDNA clones belonging to a family corresponding to the characteristics illustrated in FIG. 2 and comprising in particular a SalI restriction site and two HindIII restriction sites, with a stop codon located downstream of the first HindIII site.
[0020] The cDNA clones comprising an EcoRV and/or PstI restriction site between the two sites SalI and HindIII, or on either side of the SalI site, are particularly preferred.
[0021] Particularly advantageous constructs comprise, as nucleic acid sequences, a sequence chosen from SEQ ID No 1, SEQ ID No 2, SEQ ID No 3, SEQ ID No 4, SEQ ID No 5 and SEQ ID No 11, these sequences encoding, respectively, proteins having the sequences SEQ ID No 6, SEQ ID No 7, SEQ ID No 8, SEQ ID No 9, SEQ ID No 10 and SEQ ID No 12.
[0022] Preferred constructs comprise said nucleic acid sequences in a rapid multiplication plasmid such as pTex.
[0023] The invention is also directed toward the Leishmania strains transfected with such constructs, whether promastigote forms or amastigote forms are involved.
[0024] Transfected strains that are preferred, taking into account the vaccine applications targeted, are L. infantum strains.
[0025] Advantageously, the PSAs are produced in large amount, constitutively, in the parasites.
[0026] The invention is also directed toward a method of transfecting a Leishmania parasite, characterized in that a vector as defined above, comprising a marker, is introduced into the Leishmania parasite, the transfected parasites are selected by means of said marker, they are placed in culture in a completely defined axenic and serum-free medium, and the culture supernatant which contains the immunogenic proteins present in concentrations of the order of 10 to 20 times higher than that produced by the Leishmania mother strain is recovered.
[0027] The introduction of the vector into the parasite is, for example, carried out by electroporation.
[0028] The insertion of these nucleic acids into the parasites makes it possible to increase the infectious capacity of the latter: their ability to survive in the infected macrophage and to multiply therein is up to 5 times greater than that of the parasite not transfected with such nucleic acids.
[0029] Said PSAs are produced in large amount in the parasite culture medium supernatant. The invention is therefore also directed toward the culture medium supernatants of said genetically modified parasites, and also the PSAs isolated from these supernatants and purified.
[0030] The invention thus provides agents of great value for satisfying the industrial demand for large amounts of proteins constituting virulence/pathogenicity factors in Leishmania.
[0031] Due to their immunogenic capacity, these proteins make it possible to obtain, after immunization of animals according to conventional techniques, polyclonal antibodies and to develop monoclonal antibodies. The immunization of mice has thus made it possible to obtain anti IgG2A antibodies and that of dogs has made it possible to obtain IgG2 antibodies.
[0032] The invention is therefore also directed toward such antibodies and makes beneficial use of their properties for developing, on an industrial exportable scale, vaccine compositions against leishmania in humans or animals.
[0033] The diagnostic applications of these antibodies are also part of the invention.
[0034] Other characteristics and advantages of the invention will be given in the examples which follow, in which reference will be made to FIGS. 1 to 8, which represent, respectively:
BRIEF DESCRIPTION OF THE DRAWINGS
[0035] FIGS. 1A through 1H, FIGS. 1A through 1H form one complete view on several sheets and show the 3' alignment of the nucleotide sequences of cDNA clones according to the invention;
[0036] FIG. 2, a recapitulative diagram of the nucleotide sequences of the cDNA clones obtained after immunoscreening, with an anti-ESA monoclonal antibody, of L. amazonensis promastigote form and amastigote form expression libraries. The restriction enzyme sites are indicated above each sequence;
[0037] FIG. 3A, the location of various protein regions, characterized by their specific amino acid composition, present on the protein sequence deduced from the cDNA of the clone A3B;
[0038] FIG. 3B, a diagrammatic representation of the protein sequence deduced from the cDNA of the clone A3B encoding a PSA;
[0039] FIG. 4, the analyses of the transcripts by RT-PCR in the promastigote (P) and amastigote (A) forms;
[0040] FIG. 5, the level of production of the protein by Western blotting, using an anti-PSA antibody;
[0041] FIG. 6A, the effect of the overexpression of a PSA of L. amazonensis on the infectious capacity of the parasites after 2 h contact with promastigotes;
[0042] FIG. 6B, the effect of the overexpression of a PSA of L. amazonensis on the infectious capacity of the parasites after 48 h contact with amastigotes;
[0043] FIGS. 7A through 7F, FIGS. 7A through 7F form one complete view on several sheets and show the nucleotide sequences SEQ ID Nos 1 to 5 and 11, respectively, of the clones A3B, 2C1, 1A1, 2G1 and W2 of L. amazonensis promastigotes and amastigotes and IJ11 of L. infantum promastigotes, and the corresponding encoded amino acid sequences SEQ ID Nos 6 to 10 and 12, and
[0044] FIG. 8, the parasitic index determined during the in vitro infection of canine macrophages with a wild-type strain or selected L. infantum promastigote clones, at various incubation times.
[0045] 1--Molecular Characterization of the Major Immunogens of the ESAs of Promastigote and Amastigote Forms of L. amazonensis (Abbreviated to Lma)
[0046] This characterization was carried out by screening L. amazonensis promastigote form and amastigote form cDNA expression libraries using a monoclonal antibody directed against the ESA major immunogen.
[0047] cDNA Library Characteristics:
[0048] Two cDNA expression libraries, respectively of promastigote forms and of amastigote forms of L. amazonensis, were produced. The characteristics of these libraries are given in table I. The exponential-phase and stationary-phase parasites were mixed in order to have access to the various transcripts that may be expressed during the various stages of the in vitro culturing thereof. 5×104 phages per library were then immunoscreened with the monoclonal antibody F5 diluted to 1/500. The production of this antibody is the subject of the example in the FR patent mentioned above.
TABLE-US-00001 TABLE I cDNA library Lma LES D 4 + D 7 Promastigotes Amastigotes Harvest D 4 + D 7 7.8 109 7.8 109 Titration after packaging 350 000 500 000 Titer after amplification 8.32 107 pH/ul 2.16 108 pH/ul D 4 + D 7 = parasites harvested on the 4th day, in the exponential phase, and on the 7th day, in the stationary phase of their growth.
[0049] Isolation and Sequencing of the Clones Recognized by the Monoclonal Antibody F5
[0050] 13 clones of the promastigote library were found to be positive and 11 clones of the amastigote library were found to be positive. All these clones were isolated by secondary and tertiary screening.
[0051] The plasmid DNA of all the clones isolated was analyzed after various enzymatic digestions and the cDNAs having larger inserts, by EcoRI/XhoI digestion, were selected in order to eliminate the cDNAs that were too truncated in the 5' position. As shown in table II, the clones 1A1, 1B1, 2B3, 2C1, 2D1 and 2E1 of the promastigote cDNA library and the clones A3B, V4A, V5, W2 and W3 of the amastigote library exhibit the larger inserts.
[0052] The analysis of these clones, by determining the presence or absence of two previously selected restriction enzyme sites (HindIII and SalI), show that they exhibit strong homology of their nucleotide sequence.
[0053] Three different classes of clones were demonstrated, by double HindIII/SalI digestion, with a HindIII/SalI fragment less than 400 bp in size (clone 2G1), 500 bp in size (clones of type 2C1 and A3B) or 600 bp in size (clones of type 1A1 or W2), respectively. Thus, five types of clones, chosen according to the specific characteristics of their DNA (the size of the insert and the location of certain restriction enzyme sites) are represented in bold characters in table II.
TABLE-US-00002 TABLE II Lma promastigote cDNA library cDNA clones 1A1 1B1 1C1 1D5 1F1 2A2 2B3 2C1 2D1 2E1 2F1 2G1 B3A Size of the EcoRI/ 2.5 2.5 2-2.2 0.5 2 2(>) 2.5 2.4 2.4 2.4 2 1.7-2 1.7 XhoI inserts (kb) Restriction map SalI Y Y Y N N N Y Y Y Y N Y N HindIII 1.1 1.1 1.1 / 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 HindIII/SalI (bp) 600 600 500 N N N 600 500 500 500 N <400 N Recombinant protein expression (kDa) 45 / 40 / / / / 42.5 / / 39 ? 18 Lma amastigote cDNA library cDNA clones A3B V1B V2D V3A V4A V5 W1A W1C W2 W3 W5 EcoRI/XhoI (kb) 2.3 2-2.2 2.2 ? 2.3 2.3 2 2 2.3 2.2 1.7 Restriction map SalI Y Y Y N Y Y N N Y Y N HindIII 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 HindIII/SalI (bp) 505 500 500 N 500 500 N N 600 500< N Recombinant protein expression (kDa) 42.5 / 36.5 / 36.5 43 / / 45 / / Y = yes, for site present; N = no, for site absent; / = performed; ? = result not obtained.
[0054] Table II also gives the results relating to the ability of the clones to express a recombinant protein. IPTG was used as an inducing agent. The samples were analyzed by SDS-PAGE and immunoblotting in the presence of the antibody against promastigote form and/or amastigote form ESA, preabsorbed in the presence of E. coli lysate. Equivalent results are obtained. For clones of interest, the expression of various recombinant proteins ranging from 42.5 kDa in apparent molecular weight (clone 2C1), to 43 kDa (clone A3B) or 45 kDa (1A1 and W2) is noted.
[0055] The "sequence listing" document reports the results of the sequencing:
[0056] of the following three types of clones of the promastigote library:
[0057] the clone of type 1A1 (SEQ ID No 3), which expresses a protein, of sequence SEQ ID No 8, of higher molecular weight. The clones of type 1B1 and 2B3 are of the same type as this clone;
[0058] the clone 2C1 (SEQ ID No 2), which expresses a recombinant protein of molecular weight lower than that of the clone 1A1, having a sequence SEQ ID No 7;
[0059] the clone 2G1 (SEQ ID No 4), which has the particularity of possessing a small HindIII/SalI fragment, which expresses a recombinant protein of molecular weight lower than that of the clone 1A1, having a sequence SEQ ID No 9;
[0060] of the following two clones of the amastigote library:
[0061] the clones of type A3B (SEQ ID No 1), which express a recombinant protein of approximately 43 kDa, of sequence SEQ ID No 6 and having a 500 bp HindIII/SalI fragment, the clone V5 appearing to be identical. The clones V2D and V4A are considered to be truncated clones of the same type;
[0062] the clone W2 (SEQ ID No 5), which expresses a recombinant protein of 45 kDa, of sequence SEQ ID No 10 and which has a 600 bp HindIII/SalI fragment.
[0063] Study of the Five cDNA Sequences
[0064] The alignment of the five cDNA sequences obtained is represented in FIG. 1, where the differences between these clones are only due to the presence of a 5'-truncated sequence and/or the insertion of sequences of approximately 72 nucleotides of the 5' side. The clones thus exhibit one (clones 2C1 and A3B) or three (clones 1A1 and W2) insertions. Outside these insertion zones, the clones exhibit homologies of the order of 99% and can be considered to belong to a cDNA family. Only the clone A3B has the ATG initiation codon, the other clones being 5'-truncated. However, the A3B cDNA does not have the 39 nt sequence encoding the "splice leader" found in the 5' position on all Leishmania mRNAs.
[0065] The cDNAs of the clones A3B and 2C1 exhibit virtually total homology and are therefore considered to be identical, the cDNA of the clone 2C1 corresponding to a 5'-truncated portion of the cDNA of the clone A3B.
[0066] The clone A3B, representative of this family, was the subject of complete sequencing in both directions.
[0067] The restriction enzyme sites for each of these clones are reported in FIG. 2.
[0068] The sequences SEQ ID Nos 1 to 5 correspond, respectively, to those of the cDNAs of A3B, 2C1, 1A1, 2G1 and W2.
[0069] Analysis of the Various Deduced Protein Sequences
[0070] The translation of the various cDNA sequences into protein sequences was carried out by choosing the reading frame corresponding to that suggested by the position of the initiation codon on the plasmid pB-SK, the transcription of which is under the control of the promoter of the lacZ gene subjected to induction with IPTG.
[0071] The A3B protein exhibits the regions illustrated in FIGS. 3A and 3B. At the NH2-terminal, a hydrophobic peptide, which can be cleaved, and which is described in the literature as a secretion pathway signal peptide, is identified. This is followed by the leucine-rich repeat domain, the clone A3B possessing 6 repeats. About ten amino acids from the end of this domain is a region rich in proline, threonine and serine, hereinafter called poly P/T/S region. This region is followed by a cysteine-rich region, that can be involved in disulfide bridges. Finally, the protein sequence ends with a hydrophobic signal peptide.
[0072] The cDNAs of the clones A3B and 2C1 exhibit virtually total homology and are therefore considered to be identical, the cDNA of the clone 2C1 corresponding to a 5'-truncated portion of the cDNA of the clone A3B.
[0073] The clone A3B, representative of this family, was the subject of complete sequencing in both directions.
[0074] The restriction enzyme sites for each of these clones are reported in FIG. 2: Nt=nucleotides; ATG=initiation codon; TAG=stop codon.
[0075] Analysis on the PROSITE database shows that the A3B protein has an N-glycosylation site located at the end of each leucine-rich repeat domain, and 12 potential phosphorylation sites.
[0076] Analysis of the location of this protein on the PSORT server predicts a cytoplasmic location at 92%, which indicates that the protein is soluble. This protein is probably anchored to the surface via a glycosyl phosphatidyl inositol or GPI. The hydrophobic signal peptide can therefore be cleaved and allow anchoring of the GPI at the level of asparagine (D).
[0077] The theoretical molecular weight of the protein of the clone A3B differs by approximately 2.9 kDa from that of the 1A1 and W2 proteins, which is in agreement with the difference of 2.5 kDa observed between the corresponding recombinant proteins. This difference is due to the presence of a variable number of leucine-rich repeats or LRRs, each also exhibiting a specific amino acid composition.
[0078] The apparent and theoretical molecular weights of the four types of PSA of the invention are given in table III below.
TABLE-US-00003 TABLE III MW of the MW without recombinant Theoretical MW signal peptide Type of PSA protein (nontruncated) (3.2 kDa) 4 LRR (2G1) / 33.5 kDa 30.3 kDa 6 LRR (A3B) 42.5 kDa 38.5 kDa 35.3 kDa 7 LRR (1A1 and W2) 45 kDa 41.4 kDa 38.2 kDa
[0079] 2--Obtaining Genetically Modified Parasites:
[0080] Directional cloning of the LaPSA 38s gene into the expression vector pTex made it possible to obtain a construct capable of expressing the PSA gene in the sense position. The plasmid pTex-LaPSA 38s sense orientation and the empty vector pTex were then electroporated into the wild-type strain Leishmania infantum Mon 1 Clone 1, and the parasites were then selected with geneticin.
[0081] The study was carried out on wild-type (WT) parasites of the species L. infantum, those transfected with empty pTex (pTex) and those transfected with pTex containing the nucleotide sequence of interest (sense).
[0082] Molecular Characterization:
[0083] The analysis of the total DNA by Southern blotting shows that the sense construct is stable and amplified in the transformed strain. The results are given in FIG. 4, which gives the analyses of the transcripts by RT-PCR in the two forms, promastigotes (P) and amastigotes (A). FIG. 5 gives the level of production of the protein by Western blotting, using an anti-PSA antibody (FIG. 5A: constitutive proteins; FIG. 5B: excreted/secreted proteins).
[0084] Phenotypic Characterization of the Mutants:
[0085] The comparison of the growth kinetics between Ldi WT, Ldi pTex and Ldi Sense shows that the overexpression of LaPSA 38s does not interfere with the growth of the parasites. Only a longer lag phase is observed for the strains transformed with the wild-type strain.
[0086] The sensitivity to lysis by human complement was also studied. Recently, it was demonstrated that L. amazonensis PSA had the property of inhibiting the action of complement in vitro. The "sense" promastigotes are more sensitive to complement. The excess PSA at the surface of the parasites can thus lead to cleavage and also to a greater formation of complexes engendering increased lysis.
[0087] Study of Infectious Capacity of the Parasites
[0088] To study the effect of the overexpression of LaPSA 38s on the infectious capacity of the parasites, the first approach consisted in bringing promastigotes of the transformed strains into contact with macrophages from dog, which is the natural domestic reservoir for visceral leishmaniasis.
[0089] FIGS. 6A and 6B give the results obtained, respectively, 2 h after contact with the promastigotes and 48 h after contact with the amastigotes; in these figures, the parasitic index corresponds to the % of macrophages infected with the Sense strain×the number of parasites per macrophage/% of macrophages infected with the control strain (pTex)×the number of parasites per macrophage.
[0090] The promastigotes overexpressing LaPSA 38s exhibit twice as much infectious capacity with respect to canine macrophages. Furthermore, after phagocytosis, the amastigotes expressing the transgene possess a capacity to survive and to multiply in the parasitophorous vacuole that is significantly greater (2.5 to 5 times) than that of the control transfected with the empty vector.
[0091] 2--Molecular Characterization of the L. infantum Promastigote ESAs
[0092] The nucleotide sequence of the L. infantum promastigote clone IJ11 is given in FIG. 7 (SEQ ID No 11) along with the corresponding amino acid sequence (SEQ ID No 12).
[0093] FIG. 8 reports the parasitic index determined during the in vitro infection of canine macrophages with the wild-type strain or the various selected L. infantum promastigote form clones (MHON/MA/67/ITMAP-263, clone 2), at various incubation times. The examination of these results shows attachment of the parasites to the macrophages after 30 min, penetration of the parasites after 2 hours and survival and multiplication of the intracellular amastigotes at 48 hours.
Sequence CWU
1
1
1212526DNALeishmania amazonensis 1gacccctgtt gcgaatggcg cagtgcgtgc
gtcggctggt gctggcggcg cccctcgccg 60ctgtggtggc gctgctgctg tgcacgagca
gtgcaccggt ggcgcgtgct gcggggacga 120gcgacttcac tgaggcgcag cagacgaaca
cgctgacggt gctgcaggcg tttgcgcgtg 180cgatccctgc gcttggggac acgtggacgg
gcagcgactt ctgctcgtgg aagcacatca 240tctgcgactc ccccggcgtc ggcgtgtgga
tgggcgatgt ggattatacc ggcacgctgc 300cggagatgcc tgcgagcgtc gactacaagg
acgtcatgat cacggaactg aacttcagcg 360caatgggcca ggggctgagc gggacgctgc
ccccctcatg gagctcgctg acgtccttga 420tatcactgtg catcgaaaag tctgagaagg
tcaccggcac gctgcctgcc cagtggagct 480cgatgacgtc gctggacaac cttaacctgc
acgacacggc ggtctccggc acgctgcctg 540cccagtggag ctcgatgaag cagctgaccg
ttctggatct ggagggcact aaggtgtccg 600gcacgctgcc gtccgagtgg agtgggatgg
cgaaggccga ggccgtgcag ctggagaact 660gcggtctgtc cgggagtctg cccccctcgt
ggtctgcgat gccgaagctg cgtatcgtct 720cactgagcgg caaccacttc tgcgggtgcg
tgcccgactc gtggagggag aaggaccgcc 780tcgatgtgac catcgaggaa tggcacatgg
gcgaggactg caagcttgct aacgcctgcc 840gcccgactgc tgctccggga acgaccacga
ctaacccgcc caccaccacc ggcaccccag 900cagcctcctc tactccttct ccagggtcgg
ggtgcgaggt ggatgggtgt gaggtgtgcg 960agggggactc cgctgcgcgg tgcgccaggt
gccgtgaggg ctactccctg acggacgaga 1020agacgtgcct ggcgaaccac gatggcggcg
tggcggcggc gtcgagcgga gcggtggctg 1080ccgctgctgt gtgggcggct gtgctgttga
gcgtggggct ggtggcgtga gggtgcggcg 1140ggcacacgcg cacgcgcaca cgccgtcgtg
catcgcgtgt gctttccgcc gttgtggcgc 1200ctgcacggat gcacgggcat gcggaggcgt
gcatgcgtgt gcgcgtgcca gctcttgtgt 1260gtctctccgt gtggccagca gtcggcaccc
gcgccgatcg aatgtgcgcg cggcggcggt 1320gtgtcgcctt ggacagcgga tgcgggcgcc
cgcccctcgc cgtgtgccct gcggtctgct 1380gtgctgccgc gcgagcgacg tacggatgcg
ctgtccggcc ctcttcgacg gggctcgctt 1440gcggtgctgt gctctcgtgg tctgtgccgg
tgctgccctg gcggggtgag agctggcggg 1500ggcgtgggtg cgcgcgcggc agctctccgc
tgcgttgagg gcggcctgcc cctgcgtccg 1560cgcaccgtcg cgctctcctc gacgccactg
cgcgcgcttg ttggcttgct ttgctctgtc 1620gtgcgcactc tctcttattt tccgtttcat
tcgcctgtat tctcttctcc caccgcactg 1680cggcctcgtc accgcggccg tgcggtgcgc
aggcgggtga tgtgccgttg tgccccccct 1740ttcatggcgc gctgggccga tcgccctctt
gcctccctcc tccccctccc cctcccgccg 1800gtcctgtcaa ttgtatatcc gtggacctta
tcttcgtact gcctccgcgc ctcttccgta 1860aagcttcgtt ggcgtgtgcc gccccccgga
cgtcagcgcc gctgtgctcg catgctcacg 1920gtgcgtcccc gtgcgtgggc gtgcacgtaa
ggacatgtat atatgtatgt gtatgtatat 1980gagtatgtat atatgtacgg ttatatatag
gaatttgtgt atgttgaggt gtatgcatgt 2040gcgtgcgtat attagtgtgt gcgagcacgc
gtgttgcgcc acgctctgct gcccgcctcc 2100gctgtgcgtg tcactcgctg tgggcgcggt
ggcgggtggc gccgggtggt ggccgtgcgg 2160cgggcggggg ctcctctgtg tttctctatt
tctctgttcc ctgttgacct caaaaaaaaa 2220aaaaaaaaaa aaagtgcacg taaggacatg
tatatatgta tgtgtatgta tatgagtatg 2280tatatatgta cggttatata taggaatttg
tgtatgttga ggtgtatgca tgtgcgtgcg 2340tatattagtg tgtgcgagca cgcgtgttgc
gccacgctct gctgcccgcc tccgctgtgc 2400gtgtcactcg ctgtgggcgc ggtggcgggt
ggcgccgggt ggtggccgtg cggcgggcgg 2460gggctcctct gtgtttctct atttctctgt
tccctgttga cctcaaaaaa aaaaaaaaaa 2520aaaaaa
252621401DNALeishmania amazonensis
2cgtggacggg cagcgacttc tgctcgtgga agcacatcat ctgcgactcc cccggcgtcg
60gcgtgtggat gggcgatgtg gattataccg gcacgctgcc ggagatgcct gcgagcgtcg
120actacaagga cgtcatgatc acggaactga acttcagcgc aatgggccag gggctgagcg
180ggacgctgcc cccctcatgg agctcgctga cgtccttgat atcactgtgc atcgaaaagt
240ctgagaaggt caccggcacg ctgcctgccc agtggagctc gatgacgtcg ctggacaacc
300ttaacctgca cgacacggcg gtctccggca cgctgcctgc ccagtggagc tcgatgaagc
360agctgaccgt tctggatctg gagggcacta aggtgtccgg cacgctgccg tccgagtgga
420gtgggatggc gaaggccgag gccgtgcagc tggagaactg cggtctgtcc gggagtctgc
480ccccctcgtg gtctgcgatg ccgaagctgc gtatcgtctc actgagcggc aaccacttct
540gcgggtgcgt gcccgactcg tggagggaga aggaccgcct cgatgtgacc atcgaggaat
600ggcacatggg cgaggactgc aagcttgcta acgcctgccg cccgactgct gctccgggaa
660cgaccacgac taacccgccc accaccaccg gcaccccagc agcctcctct actccttctc
720cagggtcggg gtgcgaggtg gatgggtgtg aggtgtgcga gggggactcc gctgcgcggt
780gcgccaggtg ccgtgagggc tactccctga cggacgagaa gacgtgcgtg gcgaaccacg
840atggcggcgt ggcggcggcg tcgagcggag cggtggctgc cgctgctgtg tgggcggctg
900tgctgttgag cgtggggctg gtggcgtgag ggtgcggcgg gcccctcttc tctgtggtgc
960ccctggtgcc tgccctcgcc cccggcacgg cgtcgtcgct gccctctctc acccccacca
1020gccgacgggg agaccgacag ccacacgcgc acgcgcacac gccgtcgtgc atcgcgtgtg
1080cgtgcactta aggacatgta tatatgtatg tgtatgtata tgagtatgta tatatgtccg
1140gttatatata ggaatttgtg tatgttgagg tgtatgcatg tgcgtgcgta tattagtctg
1200tgcgagcacg cgtgttgcgc cacgctttgc tgcccgcctc cgctgtgcgt gtccctccct
1260gtgggcgcgc tgccgggtgg ccccgggtgg tgcccgtgcg gcgggcgggg gctcctctgt
1320gtttctctat ttctctgttc cctgttgacc ccaaaaaaaa aaaaaaaaaa aaaaaaaaaa
1380aaaaaaaaaa aaaaaaaaaa a
140131684DNALeishmania amazonensis 3ggacgggcag cgacttctgc tcgtggaagc
acatcatctg cgactccccc ggcgtcggcg 60tgtggatggg cgatgtggat tataccggca
cgctgccgga gatgcctgcg agcgtcgact 120acaaggacgt catgatcatg gcactggact
tcggcgcaat gggccaggga ctgagcggga 180cgctgccccc ctcatggagc tcgctgacgt
ccttgatgtc actgtggatc gaaaagtctg 240agaaggtcac cggcacgctg cctacccagt
ggagctcgat gaagcagctg acccttctgc 300atctgaaggg cactaaggtg tccggcacgc
tgccgcccga gtggagtggg atgacgtcgc 360tggacgacct taacctgcac gacacggcgg
tctccggcac gctgcctgcc cagtggagct 420cgatgaagca gctgatcgat ctggatctgg
agggcactaa ggtgtccggc acgctgccgc 480ccgagtggag tgggatggcg aaggccgagg
ccctgcagct gaagtactgc gatctgtccg 540ggagtctgcc cccctcgtgg tcttcgatgc
agaagctgcg tatcgtctca ctgagcggca 600accacttctg cgggtgcgtg cccgactcgt
ggagggagaa ggaccgcctc gatgtgacca 660tcgaggaatg gcacatgggc gaggactgca
agcttgctaa cgcctgccgc ccgactgctg 720ctccgggaac gaccacgact aacccgccca
ccaccaccgg caccccagca gcctcctcta 780ctccttctcc agggtcgggg tgcgaggtgg
atgggtgtga ggtgtgcgag ggggactccg 840ctgcgcggtg cgccaggtgc cgtgagggct
actccctgac ggacgagaag acgtgcctgg 900cgaaccacga tggcggcgtg gcggcggcgt
cgagcggagc ggtggctgcg gctgctgtgt 960gggcggctgt gctgttgagc gtggggctgg
tggcgtgagg gtgcggcggc cccctcttct 1020ctgtggtgcc cctggtgcct gccctcgccc
ccagcacggc gtcgtcgctg ccctctcacc 1080cccaccagcc gaaggggaga ccgacagcca
cacgcacacg cgcacgcgcc gtcgtgcatc 1140gcgtgtgctt tccgccgttg tggcgcctgc
gcggatgcac gggcatgcgg aggcgtgcat 1200gcgtgtgcgc gtgccagctc ttgtgtgtct
ctccgtgtgg ccagcagtcg gcacccgcgc 1260cgatcgaatg tgcgcgcggc ggcggtgtgt
cgccttggac agcggatgcg gcgcccgccc 1320ctcgccgtgt gccctgcggt ctgctgtgct
gccgcgcgag cgacgtacgg agtgcatgta 1380aggacatgta tatatgtatg tgtaggtata
tgagtatgta tatatgtacg gttatatata 1440ggaatttgtg tatgttgagg tgtatgcatg
tgcgtgcgta tattagtctg tgcgagcacg 1500cgtgttgcgc cacgctttgc tgcccgcctc
tgctgtgcgt gtcactccct gtgggcgcgc 1560tggcgggtgg cgccgggtgg tggccgtgcg
gcgggcgggg gctcctctgt gtttctctat 1620ttctctgttc cctgttgacc tcaagaaaaa
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1680aaaa
168441404DNALeishmania amazonensis
4tcggcgtgtg gatgggcgat gtggattata ccggcacgct gccggagatg cctgcgagcg
60tcgactacaa ggacgtcatg atcacggaac tgaacttcgg cgcaatgggc cagggactga
120gcgggacgct gcccccctca tggagctcga tgaagcagct gatcgatctg gatctggagg
180gcactaaggt gtccggcacg ctgccgcccg agtggagtgg gatggcgaag gccgaggccc
240tgcagctgaa gtactgcgat ctgtccggga gtctgccccc ctcgtggtct tcgatgcaga
300agctgcgtat cgtctcactg agcggcaacc acttctgcgg gtgcgtgccc gactcgtgga
360gggagaagga ccgcctcgat gtgaccatcg aggaatggca catgggcgag gactgcaagc
420ttgctaacgc ctgccgcccg actgctgctc cgggaacgac cacgactaac ccgcccacca
480ccaccggcac cccagcagcc tcctctactc cttctccagg gtcggggtgc gaggtggatg
540ggtgtgaggt gtgcgagggg gactccgctg cgcggtgcgc caggtgccgt gagggctact
600ccctgacgga cgagaagacg tgcctggcga accacgatgg cggcgtggcg gcggcgtcaa
660gcggagcggt ggctgcggct gctgtgtggg cggctgtgct gttgagcgtg gggctggtgg
720cgtgagggtg cggcgggccc ctcttctctg tggtgcccct ggtgcctgcc ctcgcccccg
780gcacggcgtc gtcgctgccc tctctcaccc ccaccagccg acggggagac cgacagccac
840acgcgcacgc gcacacgccg tcgtgcatcg cgtgtgcttt ccgccgttgt ggcgcctgca
900cggatgcacg ggcatgcgga ggcgtgcatg cgtgtgcgcg tgccagctct tgtgtgtctc
960tccgtgtggc cagcagtcgg cacccgcgcc gatcgaatgt gcgcgcggcg gcggtgtgtc
1020gccttggaca gcggatgctg gcgcccgccc ctcgcgtgtg cctcggtctg cgtgtcgtgg
1080ccgcgcgagc gacgtacgga gtgcgctgtg tgcacttaag gacatgtata tatgtatgtg
1140tatgtatatg agtatgtata tatgtacggt tatatatagg aatttgtgta tgttgaggtg
1200tatgcatgtg cgtgcgtata ttagtctgtg cgagcacgcg tgttgcgcca cgctttgctg
1260cccgcctccg ctgtgggtgt cactcgctgt gggcccggtg gcgggtggcc ccgggtggtg
1320cccgttcggc gggcgggggc tcctctgtgt ttctctattt ctctgttccc tgttgccctc
1380caaaaaaaaa aaaaaaaaaa aaaa
140451501DNALeishmania amazonensis 5ccggcgtcgg cgtgtggatg ggcgatgtgg
attataccgg cacgctgccg gagatgcctg 60cgagcgtcga ctacaaggac gtcatgatca
cggaactgaa cttcagcgca atgggccagg 120ggctgagcgg gacgctgccc ccctcatgga
gctcgctgac gtccttgata tcactgtgca 180tcgaaaagtc tgagaaggtc accggcacgc
tgcctgccca gtggagctcg atgacgtcgc 240tggacaacct taacctgcac gacacggcgg
tctccggcac gctgccgccc gagtggagtg 300ggatgacgtc gctggacgac cttaacctgc
acgacacggc ggtctccggc acgctgcctg 360cccagtggag ctcgatgaag cagctgatcg
atctggatct ggagggcact aaggtgtccg 420gcacgctgcc gcccgagtgg agtgggatgg
cgaaggccga ggccctgcag ctgaagtact 480gcgatctgtc cgggagtctg cccccctcgt
ggtcttcgat gcagaagctg cgtatcgtct 540cactgagcgg caaccacttc tgcgggtgcg
tgcccgactc gtggagggag aaggaccgcc 600tcgatgtgac catcgaggaa tggcacatgg
gcgaggactg caagcttgct aacgcctgcc 660gcccgactgc tgctccggga acgaccacga
ctaacccgcc caccaccacc ggcaccccag 720cagcctcctc tactccttct ccagggtcgg
ggtgcgaggt ggatgggtgt gaggtgtgcg 780agggggactc cgctgcgcgg tgcgccaggt
gccgtgaggg ctactccctg acggacgaga 840agacgtgcct ggcgaaccac gatggcggcg
tggcggcggc gtcaagcgga gcggtggctg 900cggctgctgt gtgggcggct gtgctgttga
gcgtggggct ggtggcgtga gggtgccgcc 960gccccctctt ctctgtggtg cccctggtgc
ctgccctcgc ccccagcacg gggtcgtcgc 1020tgccctctca cccccaccag ccgaagggga
gaccgacagc cacacgcaca cgcgcacgcg 1080ccgtcgtgca tcgcgtgtgc tttccgccgt
tgtggcgcct gcgcggatgc acgggcatgc 1140ggaggcgtgc atgcgtgtgc gcgtgccaac
tcttgtgtgt ctctccgtgt ggccagcagt 1200cggcacccgt gcacgtaagg acatgtatat
atgtatgtgt aggtatatga gtatgtatat 1260atgtacggtt atatatagga atttgtgtat
gttgaggtgt atgcatgtgc gtgcgtatat 1320tagtctgtgc gagcacgcgt gttgcgccac
gctctgctgc ccgcctctgc tgtgcgtgtc 1380actcgctgtg ggcgcgctgg cgggtggcgc
cgggtggtgg ccgtgcggcg ggcgggggct 1440cctctgtgtt tctctatttc tctgttccct
gttgacctca agaaaaaaaa aaaaaaaaaa 1500a
15016371PRTLeishmania amazonensis 6Met
Ala Gln Cys Val Arg Arg Leu Val Leu Ala Ala Pro Leu Ala Ala 1
5 10 15 Val Val Ala Leu Leu Leu
Cys Thr Ser Ser Ala Pro Val Ala Arg Ala 20
25 30 Ala Gly Thr Ser Asp Phe Thr Glu Ala Gln
Gln Thr Asn Thr Leu Thr 35 40
45 Val Leu Gln Ala Phe Ala Arg Ala Ile Pro Ala Leu Gly Asp
Thr Trp 50 55 60
Thr Gly Ser Asp Phe Cys Ser Trp Lys His Ile Ile Cys Asp Ser Pro 65
70 75 80 Gly Val Gly Val Trp
Met Gly Asp Val Asp Tyr Thr Gly Thr Leu Pro 85
90 95 Glu Met Pro Ala Ser Val Asp Tyr Lys Asp
Val Met Ile Thr Glu Leu 100 105
110 Asn Phe Ser Ala Met Gly Gln Gly Leu Ser Gly Thr Leu Pro Pro
Ser 115 120 125 Trp
Ser Ser Leu Thr Ser Leu Ile Ser Leu Cys Ile Glu Lys Ser Glu 130
135 140 Lys Val Thr Gly Thr Leu
Pro Ala Gln Trp Ser Ser Met Thr Ser Leu 145 150
155 160 Asp Asn Leu Asn Leu His Asp Thr Ala Val Ser
Gly Thr Leu Pro Ala 165 170
175 Gln Trp Ser Ser Met Lys Gln Leu Thr Val Leu Asp Leu Glu Gly Thr
180 185 190 Lys Val
Ser Gly Thr Leu Pro Ser Glu Trp Ser Gly Met Ala Lys Ala 195
200 205 Glu Ala Val Gln Leu Glu Asn
Cys Gly Leu Ser Gly Ser Leu Pro Pro 210 215
220 Ser Trp Ser Ala Met Pro Lys Leu Arg Ile Val Ser
Leu Ser Gly Asn 225 230 235
240 His Phe Cys Gly Cys Val Pro Asp Ser Trp Arg Glu Lys Asp Arg Leu
245 250 255 Asp Val Thr
Ile Glu Glu Trp His Met Gly Glu Asp Cys Lys Leu Ala 260
265 270 Asn Ala Cys Arg Pro Thr Ala Ala
Pro Gly Thr Thr Thr Thr Asn Pro 275 280
285 Pro Thr Thr Thr Gly Thr Pro Ala Ala Ser Ser Thr Pro
Ser Pro Gly 290 295 300
Ser Gly Cys Glu Val Asp Gly Cys Glu Val Cys Glu Gly Asp Ser Ala 305
310 315 320 Ala Arg Cys Ala
Arg Cys Arg Glu Gly Tyr Ser Leu Thr Asp Glu Lys 325
330 335 Thr Cys Leu Ala Asn His Asp Gly Gly
Val Ala Ala Ala Ser Ser Gly 340 345
350 Ala Val Ala Ala Ala Ala Val Trp Ala Ala Val Leu Leu Ser
Val Gly 355 360 365
Leu Val Ala 370 7286PRTLeishmania amazonensis 7Met Gly Asp Val
Asp Tyr Thr Gly Thr Leu Pro Glu Met Pro Ala Ser 1 5
10 15 Val Asp Tyr Lys Asp Val Met Ile Thr
Glu Leu Asn Phe Ser Ala Met 20 25
30 Gly Gln Gly Leu Ser Gly Thr Leu Pro Pro Ser Trp Ser Ser
Leu Thr 35 40 45
Ser Leu Ile Ser Leu Cys Ile Glu Lys Ser Glu Lys Val Thr Gly Thr 50
55 60 Leu Pro Ala Gln Trp
Ser Ser Met Thr Ser Leu Asp Asn Leu Asn Leu 65 70
75 80 His Asp Thr Ala Val Ser Gly Thr Leu Pro
Ala Gln Trp Ser Ser Met 85 90
95 Lys Gln Leu Thr Val Leu Asp Leu Glu Gly Thr Lys Val Ser Gly
Thr 100 105 110 Leu
Pro Ser Glu Trp Ser Gly Met Ala Lys Ala Glu Ala Val Gln Leu 115
120 125 Glu Asn Cys Gly Leu Ser
Gly Ser Leu Pro Pro Ser Trp Ser Ala Met 130 135
140 Pro Lys Leu Arg Ile Val Ser Leu Ser Gly Asn
His Phe Cys Gly Cys 145 150 155
160 Val Pro Asp Ser Trp Arg Glu Lys Asp Arg Leu Asp Val Thr Ile Glu
165 170 175 Glu Trp
His Met Gly Glu Asp Cys Lys Leu Ala Asn Ala Cys Arg Pro 180
185 190 Thr Ala Ala Pro Gly Thr Thr
Thr Thr Asn Pro Pro Thr Thr Thr Gly 195 200
205 Thr Pro Ala Ala Ser Ser Thr Pro Ser Pro Gly Ser
Gly Cys Glu Val 210 215 220
Asp Gly Cys Glu Val Cys Glu Gly Asp Ser Ala Ala Arg Cys Ala Arg 225
230 235 240 Cys Arg Glu
Gly Tyr Ser Leu Thr Asp Glu Lys Thr Cys Val Ala Asn 245
250 255 His Asp Gly Gly Val Ala Ala Ala
Ser Ser Gly Ala Val Ala Ala Ala 260 265
270 Ala Val Trp Ala Ala Val Leu Leu Ser Val Gly Leu Val
Ala 275 280 285
8310PRTLeishmania amazonensis 8Met Gly Asp Val Asp Tyr Thr Gly Thr Leu
Pro Glu Met Pro Ala Ser 1 5 10
15 Val Asp Tyr Lys Asp Val Met Ile Met Ala Leu Asp Phe Gly Ala
Met 20 25 30 Gly
Gln Gly Leu Ser Gly Thr Leu Pro Pro Ser Trp Ser Ser Leu Thr 35
40 45 Ser Leu Met Ser Leu Trp
Ile Glu Lys Ser Glu Lys Val Thr Gly Thr 50 55
60 Leu Pro Thr Gln Trp Ser Ser Met Lys Gln Leu
Thr Leu Leu His Leu 65 70 75
80 Lys Gly Thr Lys Val Ser Gly Thr Leu Pro Pro Glu Trp Ser Gly Met
85 90 95 Thr Ser
Leu Asp Asp Leu Asn Leu His Asp Thr Ala Val Ser Gly Thr 100
105 110 Leu Pro Ala Gln Trp Ser Ser
Met Lys Gln Leu Ile Asp Leu Asp Leu 115 120
125 Glu Gly Thr Lys Val Ser Gly Thr Leu Pro Pro Glu
Trp Ser Gly Met 130 135 140
Ala Lys Ala Glu Ala Leu Gln Leu Lys Tyr Cys Asp Leu Ser Gly Ser 145
150 155 160 Leu Pro Pro
Ser Trp Ser Ser Met Gln Lys Leu Arg Ile Val Ser Leu 165
170 175 Ser Gly Asn His Phe Cys Gly Cys
Val Pro Asp Ser Trp Arg Glu Lys 180 185
190 Asp Arg Leu Asp Val Thr Ile Glu Glu Trp His Met Gly
Glu Asp Cys 195 200 205
Lys Leu Ala Asn Ala Cys Arg Pro Thr Ala Ala Pro Gly Thr Thr Thr 210
215 220 Thr Asn Pro Pro
Thr Thr Thr Gly Thr Pro Ala Ala Ser Ser Thr Pro 225 230
235 240 Ser Pro Gly Ser Gly Cys Glu Val Asp
Gly Cys Glu Val Cys Glu Gly 245 250
255 Asp Ser Ala Ala Arg Cys Ala Arg Cys Arg Glu Gly Tyr Ser
Leu Thr 260 265 270
Asp Glu Lys Thr Cys Leu Ala Asn His Asp Gly Gly Val Ala Ala Ala
275 280 285 Ser Ser Gly Ala
Val Ala Ala Ala Ala Val Trp Ala Ala Val Leu Leu 290
295 300 Ser Val Gly Leu Val Ala 305
310 9307PRTLeishmania amazonensis 9Met Cys Val Arg Ile Leu Val
Cys Ala Ser Thr Arg Val Ala Pro Arg 1 5
10 15 Phe Ala Ala Arg Leu Arg Cys Gly Cys His Ser
Leu Trp Ala Arg Trp 20 25
30 Arg Val Ala Pro Gly Gly Ala Arg Ser Ala Gly Gly Gly Ser Ser
Val 35 40 45 Phe
Leu Tyr Phe Ser Val Pro Cys Cys Pro Pro Lys Lys Lys Lys Lys 50
55 60 Lys Lys Ile Gly Val Trp
Met Gly Asp Val Asp Tyr Thr Gly Thr Leu 65 70
75 80 Pro Glu Met Pro Ala Ser Val Asp Tyr Lys Asp
Val Met Ile Thr Glu 85 90
95 Leu Asn Phe Gly Ala Met Gly Gln Gly Leu Ser Gly Thr Leu Pro Pro
100 105 110 Ser Trp
Ser Ser Met Lys Gln Leu Ile Asp Leu Asp Leu Glu Gly Thr 115
120 125 Lys Val Ser Gly Thr Leu Pro
Pro Glu Trp Ser Gly Met Ala Lys Ala 130 135
140 Glu Ala Leu Gln Leu Lys Tyr Cys Asp Leu Ser Gly
Ser Leu Pro Pro 145 150 155
160 Ser Trp Ser Ser Met Gln Lys Leu Arg Ile Val Ser Leu Ser Gly Asn
165 170 175 His Phe Cys
Gly Cys Val Pro Asp Ser Trp Arg Glu Lys Asp Arg Leu 180
185 190 Asp Val Thr Ile Glu Glu Trp His
Met Gly Glu Asp Cys Lys Leu Ala 195 200
205 Asn Ala Cys Arg Pro Thr Ala Ala Pro Gly Thr Thr Thr
Thr Asn Pro 210 215 220
Pro Thr Thr Thr Gly Thr Pro Ala Ala Ser Ser Thr Pro Ser Pro Gly 225
230 235 240 Ser Gly Cys Glu
Val Asp Gly Cys Glu Val Cys Glu Gly Asp Ser Ala 245
250 255 Ala Arg Cys Ala Arg Cys Arg Glu Gly
Tyr Ser Leu Thr Asp Glu Lys 260 265
270 Thr Cys Leu Ala Asn His Asp Gly Gly Val Ala Ala Ala Ser
Ser Gly 275 280 285
Ala Val Ala Ala Ala Ala Val Trp Ala Ala Val Leu Leu Ser Val Gly 290
295 300 Leu Val Ala 305
10310PRTLeishmania amazonensis 10Met Gly Asp Val Asp Tyr Thr Gly Thr
Leu Pro Glu Met Pro Ala Ser 1 5 10
15 Val Asp Tyr Lys Asp Val Met Ile Thr Glu Leu Asn Phe Ser
Ala Met 20 25 30
Gly Gln Gly Leu Ser Gly Thr Leu Pro Pro Ser Trp Ser Ser Leu Thr
35 40 45 Ser Leu Ile Ser
Leu Cys Ile Glu Lys Ser Glu Lys Val Thr Gly Thr 50
55 60 Leu Pro Ala Gln Trp Ser Ser Met
Thr Ser Leu Asp Asn Leu Asn Leu 65 70
75 80 His Asp Thr Ala Val Ser Gly Thr Leu Pro Pro Glu
Trp Ser Gly Met 85 90
95 Thr Ser Leu Asp Asp Leu Asn Leu His Asp Thr Ala Val Ser Gly Thr
100 105 110 Leu Pro Ala
Gln Trp Ser Ser Met Lys Gln Leu Ile Asp Leu Asp Leu 115
120 125 Glu Gly Thr Lys Val Ser Gly Thr
Leu Pro Pro Glu Trp Ser Gly Met 130 135
140 Ala Lys Ala Glu Ala Leu Gln Leu Lys Tyr Cys Asp Leu
Ser Gly Ser 145 150 155
160 Leu Pro Pro Ser Trp Ser Ser Met Gln Lys Leu Arg Ile Val Ser Leu
165 170 175 Ser Gly Asn His
Phe Cys Gly Cys Val Pro Asp Ser Trp Arg Glu Lys 180
185 190 Asp Arg Leu Asp Val Thr Ile Glu Glu
Trp His Met Gly Glu Asp Cys 195 200
205 Lys Leu Ala Asn Ala Cys Arg Pro Thr Ala Ala Pro Gly Thr
Thr Thr 210 215 220
Thr Asn Pro Pro Thr Thr Thr Gly Thr Pro Ala Ala Ser Ser Thr Pro 225
230 235 240 Ser Pro Gly Ser Gly
Cys Glu Val Asp Gly Cys Glu Val Cys Glu Gly 245
250 255 Asp Ser Ala Ala Arg Cys Ala Arg Cys Arg
Glu Gly Tyr Ser Leu Thr 260 265
270 Asp Glu Lys Thr Cys Leu Ala Asn His Asp Gly Gly Val Ala Ala
Ala 275 280 285 Ser
Ser Gly Ala Val Ala Ala Ala Ala Val Trp Ala Ala Val Leu Leu 290
295 300 Ser Val Gly Leu Val Ala
305 310 113088DNALeishmania amazonensis 11gcgctgctgc
cgctggcgct gttgtgtgtg tgctggggcc gcgccacgca cacgcacggt 60agtgaggggg
agccgcagcg accgaccggg cggagcgggc gggcggaggg gggcgctccc 120gcccgctggt
catgctctct gtttcgctgg ccggcctctc tacgccgctg gcgtgggcgg 180agctccgcgc
tgcgtatcgc tcgcccctcg ctgcccctcc ctgcccctcc tcatgtgcac 240tgctccctcc
ctctccctcc ctctacactc ctcgctgtcc cctcggccga cctccacgga 300cacgcagacg
tgcgtgcgca tacacaccac ccctcacctc gctgctgctg ctgtgacagc 360tctacggacc
ctgcccagtc gctgcgcccc cgccacccgc ctctgtcccc cgcacgaggg 420tacctacgac
gtgccggcca ccccgctctg cccgataagc tgagctggcg ctcacgcccg 480agcaatcccc
tcacggatct gctgccgcgc cgcactgctc ttgaccctgg ctgcgaatgg 540cgctgtgcgt
gcgtcggctg gtgctggcgg cgaccctcgc cgctgtggtg gcgctgctgc 600tgtgcacgag
cagtgcgccg gtggcgcgtg ctgctgtgaa ggatgacttc actgctgcgc 660agcggacgaa
cacgctggcg gtgctggagg cgtttgggcg tgcgatccct gagcttggga 720agctgtggaa
gggcgacgac ttctgctttt gggagtcggt cgtgtgcgat gtgaccgaag 780tgtacttgtg
ggaaatcggt gcgacgtata ccggcacgct gccggagatg cctgtggacg 840tcgactacac
ggccgtcatg gtcaagcacc tcgacttttc ccaaatgggg ctggggctga 900gcggaacgct
gccggacagc tggagcaggc tgcagggact gacctcactt acgttgtcgg 960gctgcggcgt
gagcggtacg ctgcccccct cgtggcgctc gatgaagtct ttggtgtcgt 1020tgtggattga
gagttgtgaa agtgttaccg gcaagctgcc gcctgagtgg agctcgatga 1080aatcgctgag
agatctccat ctgcatggcg cgaaggtttc cggcacgctg ccgcctgagt 1140ggagcacgat
gaaatcgctg acccttctcg atctgcagga cactcaggtt accggcagtc 1200tgccgcctga
gtggagctca atgaaatcca tgaccattct cagtctgaat ggcgcgaagg 1260tttccggcac
gctgccaccc cagtggagct cgatgacatc gctgagcctt ctcagtctgg 1320agggtactca
gctctccggc acgctaccgc cccagtggag tgggatgaca tcgctggtca 1380cgctttttct
gcagggtact caggtctccg gcactctgcc gccgcagtgg agatcgatgt 1440tgaatgccga
gttcctgcag ctggagaact gcgacctgtc cggctgtttg ccccccgagt 1500gggctgcgat
gccgaagctg cgtcatgtcg aacttaaggg caaccagttc gccgggtgtg 1560tgccggactc
gtgggctcag aaggccggtc tcgttgtgga aatcgaggat aagcacacgg 1620gcaacagctg
cattgctggt gcggactgcg caacgacgac cacgaccacc actgaaccca 1680cgtccactgc
gagcccaaca gccacgccta cctctgcccc cgagacggag tgcgaggtgg 1740atgggtgtga
ggtgtgcgat ggggactccg cggcgaggtg cgccaggtgc cgtgagggct 1800acttcctgac
ggacgagagg acgtgcctgg tgtaccgcga tggcggcgtt gtggccgtgt 1860cgatcggagc
ggctgctgcc gctgttgtgt gcatggctgt gctgctgagc gtggggctgg 1920cggcgtgagg
atgccgctgc tgtcgcgcgc aggcggcggc acccgctgcg tggcacacga 1980ctgcgtgctt
gcgtgcagca ccgcgccctg cattggcgtg cgtgtgcgcg tctgtgtgtg 2040catggctgct
gacggtgcct ttcgtcctgc ctctcgctgc ctctgcctct ctccgcgtgt 2100gaatgctgtg
ggctgtgttt ggggctctcg tgcggcgctg ctgtacggct gctgcttctt 2160ctccaccctc
ctctctcgca tgccggcgag ggaggggtgg cacgtgcgcg tgtgccgctg 2220cgcttgcgag
tgcgtctgtg tgtgggcctt caccacgtgc tacggtcacg ccttctcggc 2280tggccactcg
cggcgctgag ggcggtgtgc ccttcccctc gagcgccgtc gcactctctt 2340ccgcgcgcct
gcgcgggctt cttcgtgcgc tgtgctcagc cgtgcgctct cacctctttc 2400ccttttcatt
cgcttgtctt ctctcttctc cccccgcact gcggtctccc ctcctctgcc 2460gtgcggtgcg
caggcgggtg acttgccgtt gcgtctcccc ctttcgtgga gcgctgagcc 2520gatccccctt
cggcctccct cctccctcct cccgtgggtc ctgtctgttg tacatcgtcg 2580gaccgtctct
tcgtgttgcc tctccgcacc ttccgcaaat ctgcgctcgc ctgtgccgcc 2640tctcggactt
tatccttact gtgattgtat tctcacggtg cgtctccgtg tgtgtgtgtg 2700ccacgcaccg
cttcttccat gtgtgtcctt gcttgctctc gtctgccccc ccccctctgc 2760ctcacacatt
ccgtgcgtgt gtgcatcacc gttgggcggc gacatcggtg cccgtccctg 2820ccaccctcta
ctccctcatt ctcttgccac ttcgtgggcg gtgcgtgcat gcatggatgt 2880atatacacgc
atagaggggt ggggacgcgg gggatcctct agagtcgacc tgcaggcatg 2940caagcttggc
gtaatcatgg tcatagctgt ttcctgtgtg aaattgttat ccgctcacaa 3000ttccacacaa
catacgagcc ggaagcataa agtgtaaagc ctggggtgcc taatgagtga 3060gctaactcac
attaattgcg ttgcgctc
308812464PRTLeishmania amazonensis 12Met Ala Leu Cys Val Arg Arg Leu Val
Leu Ala Ala Thr Leu Ala Ala 1 5 10
15 Val Val Ala Leu Leu Leu Cys Thr Ser Ser Ala Pro Val Ala
Arg Ala 20 25 30
Ala Val Lys Asp Asp Phe Thr Ala Ala Gln Arg Thr Asn Thr Leu Ala
35 40 45 Val Leu Glu Ala
Phe Gly Arg Ala Ile Pro Glu Leu Gly Lys Leu Trp 50
55 60 Lys Gly Asp Asp Phe Cys Phe Trp
Glu Ser Val Val Val Arg Cys Asp 65 70
75 80 Arg Ser Val Leu Gly Gly Lys Ser Val Arg Arg Ile
Pro Ala Arg Cys 85 90
95 Arg Arg Cys Leu Trp Thr Ser Thr Thr Arg Pro Ser Trp Ser Ser Thr
100 105 110 Ser Thr Phe
Pro Lys Trp Gly Trp Gly Trp Ala Glu Arg Cys Arg Thr 115
120 125 Ala Gly Ala Gly Cys Arg Asp Trp
Pro His Leu Arg Cys Arg Ala Ala 130 135
140 Ala Trp Ala Val Arg Cys Pro Pro Arg Gly Ala Arg Trp
Ser Leu Trp 145 150 155
160 Cys Arg Cys Gly Leu Arg Val Val Lys Val Leu Pro Ala Ser Cys Arg
165 170 175 Leu Ser Gly Ala
Arg Trp Asn Arg Trp Glu Ile Ser Ile Cys Met Ala 180
185 190 Arg Arg Phe Pro Ala Arg Cys Arg Leu
Ser Gly Ala Arg Trp Asn Arg 195 200
205 Trp Pro Phe Ser Ile Cys Arg Thr Leu Arg Leu Pro Ala Val
Cys Arg 210 215 220
Leu Ser Gly Ala Gln Trp Asn Pro Trp Pro Phe Ser Val Trp Met Ala 225
230 235 240 Arg Arg Phe Pro Ala
Arg Cys His Pro Ser Gly Ala Arg Trp His Arg 245
250 255 Trp Ala Phe Ser Val Trp Arg Val Leu Ser
Ser Pro Ala Arg Tyr Arg 260 265
270 Pro Ser Gly Ser Gly Met Thr Ser Leu Val Thr Leu Phe Leu Gln
Gly 275 280 285 Thr
Gln Val Ser Gly Thr Leu Pro Pro Gln Trp Arg Ser Met Leu Asn 290
295 300 Ala Glu Phe Leu Gln Leu
Glu Asn Cys Asp Leu Ser Gly Cys Leu Pro 305 310
315 320 Pro Glu Trp Ala Ala Met Pro Lys Leu Arg His
Val Glu Leu Lys Gly 325 330
335 Asn Gln Phe Ala Gly Cys Val Pro Asp Ser Trp Ala Gln Lys Ala Gly
340 345 350 Leu Val
Val Glu Ile Glu Asp Lys His Thr Gly Asn Ser Cys Ile Ala 355
360 365 Gly Ala Asp Cys Ala Thr Thr
Thr Thr Thr Thr Thr Glu Pro Thr Ser 370 375
380 Thr Ala Ser Pro Thr Ala Thr Pro Thr Ser Ala Pro
Glu Thr Glu Cys 385 390 395
400 Glu Val Asp Gly Cys Glu Val Cys Asp Gly Asp Ser Ala Ala Arg Cys
405 410 415 Ala Arg Cys
Arg Glu Gly Tyr Phe Leu Thr Asp Glu Arg Thr Cys Leu 420
425 430 Val Tyr Arg Asp Gly Gly Val Val
Ala Val Ser Ile Gly Ala Ala Ala 435 440
445 Ala Ala Val Val Cys Met Ala Val Leu Leu Ser Val Gly
Leu Ala Ala 450 455 460
User Contributions:
Comment about this patent or add new information about this topic: